Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shinichi Matsuda
Prodromal Signs and Symptoms of Serious Infections With Tocilizumab Treatment for Rheumatoid Arthritis: Text Mining of the Japanese Postmarketing Adverse Event-Reporting Database
Modern Rheumatology
Medicine
Rheumatology
Related publications
Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients With Rheumatoid Arthritis in Japan
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Immunotherapy of Tocilizumab for Rheumatoid Arthritis
Journal of Clinical & Cellular Immunology
Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS)
BioDrugs
Medicine
Biotechnology
Pharmacology
Serious Adverse Drug Events Reported to the Food and Drug Administration (FDA): Analysis of the FDA Adverse Event Reporting System (FAERS) 2006-2011 Database
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Incidence of Gastrointestinal Perforations in Patients With Rheumatoid Arthritis Treated With Tocilizumab From Clinical Trial, Postmarketing, and Real-World Data Sources
Rheumatology and Therapy
Prm87 - Critical Evaluation of Various Data Mining Algorithms Used for Signal Detection in Fda Adverse Event Reporting System Database
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients
Modern Rheumatology
Medicine
Rheumatology
Tocilizumab, a Humanized Anti-Interleukin-6 Receptor Antibody, for Treatment of Rheumatoid Arthritis
Open Access Rheumatology: Research and Reviews
Rheumatology
Analysis of Adverse Events Associated With the Anti-Allergic Agents Rx-To-Otc-Switched Using Data Mining of the Japanese Adverse Drug Event Report (JADER) Database
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)